Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Fetal safety of macrolides.

Bahat Dinur A, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, Levy A.

Antimicrob Agents Chemother. 2013 Jul;57(7):3307-11. doi: 10.1128/AAC.01691-12. Epub 2013 May 6.

2.

Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy.

Daniel S, Matok I, Gorodischer R, Koren G, Uziel E, Wiznitzer A, Levy A.

J Rheumatol. 2012 Nov;39(11):2163-9. doi: 10.3899/jrheum.120453. Epub 2012 Sep 15.

PMID:
22984274
3.

The safety of metoclopramide use in the first trimester of pregnancy.

Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A.

N Engl J Med. 2009 Jun 11;360(24):2528-35. doi: 10.1056/NEJMoa0807154.

4.

The safety of H(2)-blockers use during pregnancy.

Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Uziel E, Levy A.

J Clin Pharmacol. 2010 Jan;50(1):81-7. doi: 10.1177/0091270009350483. Epub 2009 Sep 29.

PMID:
19789371
5.

Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study.

Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, Wohlfahrt J, Melbye M.

BMJ. 2014 Mar 11;348:g1908. doi: 10.1136/bmj.g1908.

6.

The safety of fetal exposure to proton-pump inhibitors during pregnancy.

Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R.

Dig Dis Sci. 2012 Mar;57(3):699-705. doi: 10.1007/s10620-011-1940-3. Epub 2011 Oct 30.

PMID:
22038541
7.

The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study.

Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L, De Santis M, Merlob P, Stahl B, Eleftheriou G, Maňáková E, Hubičková-Heringová L, Youngster I, Berkovitch M.

Drug Saf. 2012 Jul 1;35(7):589-98. doi: 10.2165/11630920-000000000-00000.

PMID:
22702640
8.

The safety of macrolides during lactation.

Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M.

Breastfeed Med. 2009 Dec;4(4):197-200. doi: 10.1089/bfm.2008.0135.

PMID:
19366316
9.

Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations.

Matok I, Gorodischer R, Koren G, Landau D, Wiznitzer A, Levy A.

Br J Clin Pharmacol. 2009 Dec;68(6):956-62. doi: 10.1111/j.1365-2125.2009.03544.x.

10.

Safety of macrolides during pregnancy.

Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S.

Am J Obstet Gynecol. 2013 Mar;208(3):221.e1-8. doi: 10.1016/j.ajog.2012.12.023. Epub 2012 Dec 16.

11.

Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study.

Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I, Berkovitch M, Ornoy A.

Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):31-4. doi: 10.1016/j.ejogrb.2008.07.008. Epub 2008 Aug 29.

PMID:
18760873
12.

Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis.

Cooper WO, Ray WA, Griffin MR.

Obstet Gynecol. 2002 Jul;100(1):101-6.

PMID:
12100810
13.

Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway.

Romøren M, Lindbæk M, Nordeng H.

Br J Clin Pharmacol. 2012 Dec;74(6):1053-62. doi: 10.1111/j.1365-2125.2012.04286.x.

14.

Use of macrolides during pregnancy and the risk of birth defects: a population-based study.

Bérard A, Sheehy O, Zhao JP, Nordeng H.

Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1241-8. doi: 10.1002/pds.3900. Epub 2015 Oct 29.

PMID:
26513406
15.

Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations.

Goldberg O, Koren G, Landau D, Lunenfeld E, Matok I, Levy A.

J Clin Pharmacol. 2013 Sep;53(9):991-5. doi: 10.1002/jcph.139. Epub 2013 Jul 20.

PMID:
23873250
16.

Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides.

Sørensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schønheyder HC.

Scand J Infect Dis. 2003;35(2):104-6.

PMID:
12693559
17.

The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study.

Shlomo M, Gorodischer R, Daniel S, Wiznitzer A, Matok I, Fishman B, Koren G, Levy A.

Drug Saf. 2017 Jul 21. doi: 10.1007/s40264-017-0573-7. [Epub ahead of print]

PMID:
28733971
18.

Prophylactic antibiotics for inhibiting preterm labour with intact membranes.

Flenady V, Hawley G, Stock OM, Kenyon S, Badawi N.

Cochrane Database Syst Rev. 2013 Dec 5;(12):CD000246. doi: 10.1002/14651858.CD000246.pub2. Review.

PMID:
24307518
19.

Association between antibiotic prescribing in pregnancy and cerebral palsy or epilepsy in children born at term: a cohort study using the health improvement network.

Meeraus WH, Petersen I, Gilbert R.

PLoS One. 2015 Mar 25;10(3):e0122034. doi: 10.1371/journal.pone.0122034. eCollection 2015.

20.

The effect of second-trimester antibiotic therapy on the rate of preterm birth.

Morency AM, Bujold E.

J Obstet Gynaecol Can. 2007 Jan;29(1):35-44. Review.

PMID:
17346476

Supplemental Content

Support Center